Plant Name: Colchicum robustum
Taxonomic Information:
Plant ID: NPO7197
Plant Latin Name: Colchicum robustum
Taxonomy Genus: Colchicum
Taxonomy Family: Colchicaceae
Plant External Links:
NCBI TaxonomyDB:
481258
Plant-of-the-World-Online:
n.a.
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| ACHE; | |
| FLT3; CSNK2A1; | |
| CA4; CA12; CA7; | |
| ESR2; | |
| NOX4; HSD17B1; | |
| MMP12; | |
| HIF1A; | |
| THPO; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 2.338E-10 | 5.091E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, NOX4 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 2.753E-09 | 2.998E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 5.576E-08 | 2.024E-04 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 4.867E-08 | 2.024E-04 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, NOX4 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 2.109E-07 | 5.740E-04 | CA12, CA4, CA7 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 6.146E-07 | 1.338E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 8.175E-07 | 1.485E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 3.274E-06 | 3.100E-03 | CA12, CA4, CA7 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 3.856E-06 | 3.498E-03 | CYP1A1, CYP1A2 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 6.049E-06 | 5.269E-03 | CA12, CA4, CA7 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 7.636E-06 | 5.938E-03 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 5.896E-09 | 8.549E-07 | HSD17B1, ALOX5, CYP1A1, CYP1B1, PTGS2, CYP19A1 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 1.476E-08 | 1.070E-06 | HSD17B1, CYP1A2, CYP1A1, CYP1B1, CYP3A4, CYP19A1 |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 1.694E-06 | 4.094E-05 | AR, GSK3B, CDK6, FLT3, MMP2, PTGS2, HIF1A, TP53, MMP9 |
| Unclassified | Unclassified | hsa01100 | Metabolic pathways | 1.306E-06 | 3.786E-05 | MAOA, ALOX15, AKR1B1, ALOX12, PTGS2, CYP3A4, CYP19A1, HSD17B10, PKM, HSD17B1, ALOX5, CYP1A2, CYP1A1, CD38, XDH |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 7.751E-07 | 2.810E-05 | APP, MAOA, ALOX5, ALOX15, ALOX12, PTGS2 |
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 1.372E-07 | 6.632E-06 | CA12, CA2, CA4, CA7 |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 5.018E-06 | 9.096E-05 | MAOA, CYP1A2, CYP1A1, CYP1B1 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 3.627E-06 | 7.514E-05 | CYP1A2, CYP1A1, CYP1B1, CYP3A4, PTGS2 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 2.924E-05 | 4.711E-04 | ALOX5, ALOX15, ALOX12, PTGS2 |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 3.975E-05 | 5.764E-04 | PKM, FLT3, TP53, HIF1A |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 5.573E-05 | 6.735E-04 | CYP1A2, CYP1A1, CYP1B1, CYP3A4 |
| 09150 Organismal Systems | 09154 Digestive system | hsa04976 | Bile secretion | 4.997E-05 | 6.586E-04 | CA2, CYP3A4, CFTR, ABCG2 |
| 09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 1.959E-04 | 1.671E-03 | ABCC1, CDK6, CYP1B1, PTGS2, TP53, MMP9 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 1.825E-04 | 1.653E-03 | MMP2, ESR1, MMP9, ESR2 |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 2.797E-04 | 1.929E-03 | MMP2, TP53, HIF1A, ESR1, MMP9 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05169 | Epstein-Barr virus infection | 2.734E-04 | 1.929E-03 | GSK3B, SYK, CSNK2A1, CD38, TP53 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04064 | NF-kappa B signaling pathway | 1.433E-04 | 1.385E-03 | SYK, CSNK2A1, PARP1, PTGS2 |
| 09160 Human Diseases | 09161 Cancers | hsa05203 | Viral carcinogenesis | 2.927E-04 | 1.929E-03 | POLB, CDK6, PKM, SYK, TP53 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04919 | Thyroid hormone signaling pathway | 3.573E-04 | 2.253E-03 | GSK3B, TP53, ESR1, HIF1A |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05162 | Measles | 6.112E-04 | 3.692E-03 | GSK3B, CDK6, CSNK2A1, TP53 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 7.609E-05 | 8.220E-04 | CYP1A2, ALOX15, CYP3A4 |
| 09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 2.167E-04 | 1.745E-03 | MMP2, MMP9, TP53 |
| 09160 Human Diseases | 09163 Neurodegenerative diseases | hsa05010 | Alzheimer's disease | 1.342E-03 | 6.948E-03 | APP, GSK3B, MAPT, HSD17B10 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04917 | Prolactin signaling pathway | 1.139E-03 | 6.115E-03 | GSK3B, ESR1, ESR2 |
| 09130 Environmental Information Processing | 09131 Membrane transport | hsa02010 | ABC transporters | 2.675E-04 | 1.929E-03 | ABCC1, CFTR, ABCG2 |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 8.458E-04 | 4.906E-03 | CYP1A2, CYP1A1, CYP3A4 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 1.006E-03 | 5.612E-03 | MAOA, CYP1A2, CYP3A4 |
| 09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 2.095E-03 | 9.494E-03 | GSK3B, AR, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05222 | Small cell lung cancer | 1.900E-03 | 9.390E-03 | CDK6, PTGS2, TP53 |
| 09150 Organismal Systems | 09151 Immune system | hsa04640 | Hematopoietic cell lineage | 2.029E-03 | 9.489E-03 | THPO, FLT3, CD38 |
| 09150 Organismal Systems | 09155 Excretory system | hsa04964 | Proximal tubule bicarbonate reclamation | 1.943E-03 | 9.390E-03 | CA2, CA4 |
| 09100 Metabolism | 09110 Biosynthesis of other secondary metabolites | hsa00232 | Caffeine metabolism | 7.937E-05 | 8.220E-04 | CYP1A2, XDH |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
| C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MMP12; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | MMP12; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | MMP12; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | FLT3; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | FLT3; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
| NA: NA | GIST | NA | FLT3; |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
| C00-D49: Neoplasms | Cancer | C00-C96 | CSNK2A1; FLT3; ACHE; HIF1A; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | FLT3; HIF1A; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | FLT3; |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1; |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1; |
| C00-D49: Neoplasms | Breast cancer | C50 | FLT3; CYP19A1; |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MMP12; |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
| C00-D49: Neoplasms | AML | NA | FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
| C00-D49: Neoplasms | CLL | NA | FLT3; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; ACHE; |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A; |
| I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
